Ключевые слова:
хронический миелолейкоз, цитогенетическое исследование, хромосомные нарушения, робертсоновская транслокация.Библиографические ссылки
Chen Z, Shao C, Wang W, et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017;31(3):585-592. doi: 10.1038/leu.2016.231.
Crisà E., Nicolosi M, Ferri V, et al. Atypical chronic myeloid leukemia: where are we now? International Journal of Molecular Sciences. 2020; 21(18):6862.
Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y.
Ertz-Archambault N, Kelemen K. Relapse and cytogenetic evolution in myeloid neoplasms. Panminerva Med. 2017; 59(4):308-319. doi: 10.23 736/S0031-0808.17.03380-8.
Jaiswal SK, Upadhyay A, Ali A, Upadhyay SK, Kumar A, et al. Two Familial Cases of Robertsonian Transloacations 13; 14 and Its Clinical Consequences. J Genet Syndr Gene Ther. 2016; 7:283. doi:10.4172/2157-7412.1000283.
Krishna Chandran R, Geetha N, Sakthivel KM, et al. Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia. Front Oncol. 2019; 9:88. doi: 10.3389/fonc.2019.00088.
Lee M. H., Song A., Li J. Y. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report. Diagnostic Pathology. 2024;19(1):21.
McGowan-Jordan J., Simons A., Schmid M. ISCN: An international system for human cytogenomic nomenclature. Basel, New York: Karger; 2016. – 140 p.
Molica M., Massaro F., Breccia M. Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update. Expert review of molecular diagnostics. 2017;17(11):1001-1008. doi: 10.1080/14737159.2017.1383156.
Ochi Y, Yoshida K, Huang YJ, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun. 2021;12(1):2833. doi: 10.1038/s41467-021-23097-w.
Poot M, Hochstenbach R. Prevalence and Phenotypic Impact of Robertsonian Translocations. Mol Syndromol. 2021; 12(1):1-11. doi: 10.1159/ 000512676.
Schoemaker MJ, Jones ME, Higgins CD, et al. Mortality and Cancer Incidence in Carriers of Balanced Robertsonian Translocations: A National Cohort Study. Am J Epidemiol. 2019;188(3):500-508. doi: 10.1093/aje/kwy266.
Sobernig CM, Fischer HJ, Rink L, Jakobs J. Increase of Intracellular Zinc Levels Rather Than Zinc Influx Inhibits Interleukin-2 Production in Zinc Supplemented Jurkat Cells. Cell Biochem Funct. 2025;43(7):e70098. doi: 10.1002/cbf.70098.
Son H.J., Lee J.H. Novel Four-Way Variant Translocation, t(1;9;22;16)(q21;q34;q11.2;q24), in a Patient with Chronic Myeloid Leukemia. Diagnostics (Basel). 2024;14(3):303. doi: 10.3390/diagnostics14030303.
Tunç E, Ilgaz S. Robertsonian translocation (13;14) and its clinical manifestations: a literature review. Reprod Biomed Online. 2022; 45(3): 563-573. doi: 10.1016/j.rbmo.2022.05.019. Epub 2022 May 29. PMID: 35810081.